Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

June 04, 2021 By The ASCO Post Staff

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or no evidence of disease (Abstract LBA5).

Related Content